- Home
- BCYC vs ARVN Comparison
BCYC vs ARVN Comparison
Compare BCYC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- ARVN
- Stock Information
- Founded
- BCYC 2009
- ARVN 2015
- Country
- BCYC United Kingdom
- ARVN United States
- Employees
- BCYC N/A
- ARVN N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- BCYC Health Care
- ARVN Health Care
- Exchange
- BCYC Nasdaq
- ARVN Nasdaq
- Market Cap
- BCYC 565.5M
- ARVN 676.2M
- IPO Year
- BCYC 2019
- ARVN 2018
- Fundamental
- Price
- BCYC $8.18
- ARVN $9.59
- Analyst Decision
- BCYC Buy
- ARVN Buy
- Analyst Count
- BCYC 11
- ARVN 23
- Target Price
- BCYC $22.91
- ARVN $17.61
- AVG Volume (30 Days)
- BCYC 284.7K
- ARVN 2.5M
- Earning Date
- BCYC 10-31-2025
- ARVN 11-05-2025
- Dividend Yield
- BCYC N/A
- ARVN N/A
- EPS Growth
- BCYC N/A
- ARVN N/A
- EPS
- BCYC N/A
- ARVN N/A
- Revenue
- BCYC $19,281,000.00
- ARVN $372,800,000.00
- Revenue This Year
- BCYC N/A
- ARVN N/A
- Revenue Next Year
- BCYC N/A
- ARVN N/A
- P/E Ratio
- BCYC N/A
- ARVN N/A
- Revenue Growth
- BCYC N/A
- ARVN 299.57
- 52 Week Low
- BCYC $6.10
- ARVN $5.90
- 52 Week High
- BCYC $25.39
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- BCYC 53.38
- ARVN 58.63
- Support Level
- BCYC $7.65
- ARVN $9.01
- Resistance Level
- BCYC $8.42
- ARVN $9.68
- Average True Range (ATR)
- BCYC 0.49
- ARVN 0.48
- MACD
- BCYC -0.05
- ARVN -0.07
- Stochastic Oscillator
- BCYC 40.38
- ARVN 53.64
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.